Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBITDA: 2014-2025

Historic EBITDA for CytomX Therapeutics (CTMX) over the last 11 years, with Sep 2025 value amounting to -$14.2 million.

  • CytomX Therapeutics' EBITDA fell 344.95% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 101.55%. This contributed to the annual value of $31.8 million for FY2024, which is 6670.45% up from last year.
  • Latest data reveals that CytomX Therapeutics reported EBITDA of -$14.2 million as of Q3 2025, which was down 11,698.33% from -$120,000 recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' EBITDA peaked at $23.5 million during Q1 2025, and registered a low of -$35.1 million during Q4 2021.
  • Moreover, its 3-year median value for EBITDA was $995,000 (2023), whereas its average is $3.7 million.
  • Data for CytomX Therapeutics' EBITDA shows a peak YoY increase of 1,795.78% (in 2024) and a maximum YoY decrease of 505.57% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows CytomX Therapeutics' EBITDA stood at -$35.1 million in 2021, then soared by 77.30% to -$8.0 million in 2022, then surged by 112.48% to $995,000 in 2023, then skyrocketed by 1,795.78% to $18.9 million in 2024, then slumped by 344.95% to -$14.2 million in 2025.
  • Its EBITDA stands at -$14.2 million for Q3 2025, versus -$120,000 for Q2 2025 and $23.5 million for Q1 2025.